Cannabis Rescheduling Explained Without the Hype

Cannabis rescheduling is making headlines. But beneath the optimism, speculation and political noise, the real implications are more precise and more limited than many assume.

In a newly released video from VERDANT Strategies, Hirsh Jain, founder of Ananda Strategy and VERDANT’s director of market intelligence, offers a clear-eyed explanation of what just happened, why it matters and where expectations need to be recalibrated.

The conversation is not about shortcuts or predictions. It is about understanding how the process works and what operators should realistically prepare for next.

What Just Happened

On December 18, President Donald Trump signed an executive order directing the attorney general to complete the rulemaking process to move cannabis from Schedule I to Schedule III under the Controlled Substances Act.

If finalized, this would mark the most significant change to federal cannabis policy since the Act was enacted in 1971. It would also represent the first time the U.S. government formally acknowledges that cannabis has accepted medical use, something incompatible with Schedule I classification.

That distinction matters. But it is equally important to be clear about what rescheduling does not do.

Cannabis would remain federally illegal. It would remain a controlled substance. And the existing state-by-state market structure would remain intact.

What the President Can and Cannot Do

The executive order did not itself reschedule cannabis. As Jain explains, the president does not have unilateral authority to do that.

What the order does is instruct the attorney general to complete a process that has already been underway for years. That process began in 2022 and rests on a substantial legal and scientific foundation.

Timing remains uncertain. There has been speculation that a final rule could be issued early this year, but no firm timeline has been established.

What is clear is that the groundwork has already been laid.

Why the Legal Foundation Is Strong

Jain outlines three pillars supporting the rescheduling effort.

First, a comprehensive scientific and medical review by the Department of Health and Human Services concluded that cannabis has accepted medical use.

Second, an Office of Legal Counsel memo analyzed how the Controlled Substances Act’s scheduling factors apply to cannabis and confirmed the attorney general’s authority to act.

Third, a detailed administrative record was developed through evidentiary hearings before a DEA administrative law judge. Those hearings included expert testimony and findings on medical use, safety and abuse potential.

Legal challenges are expected, particularly from prohibitionist groups. But courts traditionally defer to agency decisions that are supported by a strong administrative record. According to Jain, this rescheduling effort is unusually well supported by that standard.

If the rule survives litigation, it would become effective 30 days after publication in the Federal Register.

A Moment Decades in the Making

Rescheduling did not originate in Washington.

Jain traces its roots to the medical cannabis movement that emerged in California during the HIV/AIDS crisis of the late 1980s and early 1990s. As the federal government failed to respond, patients, caregivers and local governments acted.

Over the following decades, state medical cannabis programs expanded across the country. Today, roughly 40 states allow medical use.

That reality slowly eroded the federal government’s ability to credibly maintain that cannabis has no accepted medical value. Rescheduling, in this sense, reflects a bottom-up policy shift driven by lived experience rather than ideology.

Research Gets Easier, Not Effortless

Moving cannabis to Schedule III would lower barriers to research in meaningful ways. It reduces administrative friction and makes it easier for universities and federally authorized researchers to conduct clinical trials.

Still, Jain emphasizes that this is not a cure-all. DEA registration requirements, FDA oversight, sourcing limitations and funding constraints remain. Research becomes more feasible, not fully normalized.

280E Relief Comes With Real Limits

For operators, the most closely watched implication is IRS Code Section 280E.

Once cannabis is no longer classified as a Schedule I or II substance, 280E should no longer apply. That change could significantly reduce effective tax rates and alter operator economics across the industry.

But Jain urges caution. Many companies carry unresolved tax liabilities from prior years. Whether relief applies retroactively or only prospectively depends on IRS guidance and judicial interpretation.

There is also a market dynamic to consider. A portion of any tax savings is likely to be passed on to consumers through lower prices, similar to what happened after California repealed its cultivation tax. Lower prices help legal operators compete with the illicit market, but they do not automatically translate into higher margins.

Capital Markets and the Uplisting Question

Rescheduling may attract new investors and reduce the cost of capital. Some banks may become more comfortable serving cannabis businesses under Schedule III.

However, major banking barriers remain as long as cannabis is federally illegal.

The largest unresolved issue is access to major U.S. stock exchanges. Jain highlights the contradiction of Canadian cannabis companies accessing U.S. capital markets while compliant U.S. operators cannot.

Meaningful progress on uplisting likely requires explicit guidance from federal authorities or congressional action. If that guidance arrives, the impact would be transformational. Until then, rescheduling alone does not solve the problem.

State-Level and Global Implications

Rescheduling may influence state-level debates, particularly in Republican-led states where cannabis reform has stalled. A federal acknowledgment of medical value provides political cover that did not previously exist.

Globally, the implications are broader. For decades, the U.S. exported cannabis prohibition through international treaties and diplomacy. A shift in federal classification could open new regulatory space across Europe, Latin America and other regions, accelerating medical cannabis access worldwide.

A Structural Reset, Not a Finish Line

Jain’s central message is restraint.

Rescheduling corrects one of the most fundamental contradictions in U.S. cannabis policy. But it does not end prohibition. It does not instantly unlock banking, uplisting or interstate commerce. It does not erase years of accumulated tax liabilities or repair balance sheets overnight.

The operators best positioned to benefit will be those who treat this moment as a structural reset. That means cleaning up finances, strengthening compliance, retaining talent and preparing for a more rational and competitive market.

Rescheduling is not the end of the story. It is the opening of a new chapter.